Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Eli Lilly and Company
Eli Lilly and Company News
Eli Lilly and Company Quantitative Score
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Eli Lilly and Company Earnings & Revenue
Eli Lilly and Company Financials
Table Compare
Compare LLY metrics with: | |||
|---|---|---|---|
Earnings & Growth | LLY | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | LLY | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | LLY | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | LLY | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Eli Lilly and Company Income
Eli Lilly and Company Balance Sheet
Eli Lilly and Company Cash Flow
Eli Lilly and Company Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Buy |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Eli Lilly and Company Dividends
| Yield (TTM) | Dividend (TTM) | |
|---|---|---|
Infinity% | 5.0300 |
| Payment Date | Dividend | Frequency |
|---|---|---|
| 2024-09-10 | 1.3 | Quarterly |
| 2024-06-10 | 1.3 | Quarterly |
| 2024-03-08 | 1.3 | Quarterly |
| 2023-12-08 | 1.13 | Quarterly |
| 2023-09-08 | 1.13 | Quarterly |
Historical Market Cap
Shares Outstanding
Eli Lilly and Company Executives
| Name | Role |
|---|---|
| Mr. David A. Ricks | Chairman, Chief Executive Officer & President |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology |
| Ms. Anat Hakim J.D. | Executive Vice President, General Counsel & Secretary |
| Mr. Jacob S. Van Naarden | Executive Vice President & President of Loxo |
| Mr. Jeffrey N. Simmons | Senior Vice President & President of Elanco Animal Health |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. David A. Ricks | Chairman, Chief Executive Officer & President | Male | 1968 | 6.29M |
| Dr. Daniel M. Skovronsky M.D., Ph.D. | EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology | 1974 | 3.82M | |
| Ms. Anat Hakim J.D. | Executive Vice President, General Counsel & Secretary | Female | 1969 | 2.81M |
| Mr. Jacob S. Van Naarden | Executive Vice President & President of Loxo | Male | 1985 | 2.38M |
| Mr. Jeffrey N. Simmons | Senior Vice President & President of Elanco Animal Health | Male | 1967 | 1.73M |
Eli Lilly and Company Insider Trades
| Date | 15 Jul |
| Name | Brooks Gordon J. |
| Role | Interim CFO, Group VP |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 15 Jul |
| Name | Brooks Gordon J. |
| Role | Interim CFO, Group VP |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 16 Feb |
| Name | Brooks Gordon J. |
| Role | Interim CFO, Group VP |
| Transaction | Disposed |
| Type | |
| Shares | 278 |
| Date | 15 Jul |
| Name | Brooks Gordon J. |
| Role | Interim CFO, Group VP |
| Transaction | Disposed |
| Type | |
| Shares | 741 |
| Date | 15 Jul |
| Name | Sulzberger Gabrielle |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 10 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 15 Jul | Brooks Gordon J. | Interim CFO, Group VP | Disposed | 0 | |
| 15 Jul | Brooks Gordon J. | Interim CFO, Group VP | Disposed | 0 | |
| 16 Feb | Brooks Gordon J. | Interim CFO, Group VP | Disposed | 278 | |
| 15 Jul | Brooks Gordon J. | Interim CFO, Group VP | Disposed | 741 | |
| 15 Jul | Sulzberger Gabrielle | Director | Acquired | A-Award | 10 |